Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech Future Looking Rosy

BIO Convention: Mood is buoyant at industry’s annual conference

by Rick Mullin
June 30, 2014 | A version of this story appeared in Volume 92, Issue 26

[+]Enlarge
Credit: BIO
Rosie the Riveters danced above the flight deck of the U.S.S. Midway at the BIO welcome soiree.
Women dressed as Rosie the Riveter perform on a stage on a ship above a bar.
Credit: BIO
Rosie the Riveters danced above the flight deck of the U.S.S. Midway at the BIO welcome soiree.

High above the flight deck of the U.S.S. Midway, aboard which the Biotechnology Industry Organization (BIO) hosted a welcome party for its annual convention in San Diego last Monday, “Rosie” was written large in red lights. The effect accompanied a dance routine featuring women dressed as Rosie the Riveter, but the reference to the adjective “rosy” was both overt and apropos.

The biopharmaceutical sector is performing strongly this year, and forecasts are for solid growth to at least 2020. A spike in initial public stock offerings, advances in late-stage product development, the introduction of new products, and a shift in corporate emphasis to specialty pharmaceuticals suggested to attendees that the business is maturing.

A report released at the convention by En­gland-based market analysts Evaluate sees biologics accounting for more than 50% of the top 100 drugs on the market by 2020. The firm anticipates 5% growth for the overall pharmaceutical market to more than $1 trillion by 2020.

Merck Serono was among the biopharmaceutical firms at BIO with products on the threshold of approval. TH-302, a drug for soft-tissue sarcoma that Merck Serono developed in partnership with Threshold Pharmaceuticals, entered Phase III clinical trials last year.

Second Genome, which focuses on microbiome proteomics, exemplified the firms at the event that are moving biotech drug research beyond genomics. “There is definite excitement afoot,” Mohan S. Iyer, the firm’s chief business officer, told C&EN. “Pharma is realizing that a new look through the microbiome lens could lead to a whole new set of tractable, druggable targets.”

The conference’s two keynote luncheon speakers, entrepreneur Sir Richard Branson and former secretary of state Hillary Clinton, spoke with some authority on the topic of risk. Clinton also mentioned a conversation with a woman—the creator of a small biotech firm—who told her that women are not made to feel welcome in the industry.

“She asked me if I would say that today,” Clinton said at the end of her onstage interview with BIO CEO James Greenwood. “So, I just said it.”

Advertisement

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.